AbbVie Management

Management criteria checks 1/4

AbbVie's CEO is Robert Michael, appointed in Jul 2024, has a tenure of less than a year. total yearly compensation is $14.44M, comprised of 9.9% salary and 90.1% bonuses, including company stock and options. directly owns 0.006% of the company’s shares, worth €16.59M. The average tenure of the management team and the board of directors is 1.2 years and 11.9 years respectively.

Key information

Robert Michael

Chief executive officer

US$14.4m

Total compensation

CEO salary percentage9.9%
CEO tenureless than a year
CEO ownership0.006%
Management average tenure1.2yrs
Board average tenure11.9yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Robert Michael's remuneration changed compared to AbbVie's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

US$5b

Jun 30 2024n/an/a

US$5b

Mar 31 2024n/an/a

US$6b

Dec 31 2023US$14mUS$1m

US$5b

Sep 30 2023n/an/a

US$6b

Jun 30 2023n/an/a

US$9b

Mar 31 2023n/an/a

US$8b

Dec 31 2022US$10mUS$1m

US$12b

Sep 30 2022n/an/a

US$13b

Jun 30 2022n/an/a

US$13b

Mar 31 2022n/an/a

US$12b

Dec 31 2021US$12mUS$1m

US$11b

Sep 30 2021n/an/a

US$7b

Jun 30 2021n/an/a

US$7b

Mar 31 2021n/an/a

US$5b

Dec 31 2020US$13mUS$1m

US$5b

Sep 30 2020n/an/a

US$7b

Jun 30 2020n/an/a

US$7b

Mar 31 2020n/an/a

US$8b

Dec 31 2019US$9mUS$907k

US$8b

Sep 30 2019n/an/a

US$3b

Jun 30 2019n/an/a

US$4b

Mar 31 2019n/an/a

US$5b

Dec 31 2018US$3mUS$554k

US$6b

Compensation vs Market: Robert's total compensation ($USD14.44M) is above average for companies of similar size in the BG market ($USD4.36M).

Compensation vs Earnings: Robert's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.


CEO

Robert Michael (54 yo)

less than a year

Tenure

US$14,441,320

Compensation

Mr. Robert A. Michael served as Chief Operating Officer at AbbVie Inc. since June 29, 2023 until July 01, 2024 and served as its President since June 23, 2022 until July 01, 2024 also serves as its CEO and...


Leadership Team

NamePositionTenureCompensationOwnership
Richard Gonzalez
Executive Chairman11.9yrsUS$25.66m0.022%
€ 65.5m
Robert Michael
CEO & Directorless than a yearUS$14.44m0.0056%
€ 16.6m
Scott Reents
Executive VP & CFO2.5yrsUS$10.19m0.00087%
€ 2.6m
Azita Saleki-Gerhardt
Executive VP & COOless than a yearUS$9.30m0.011%
€ 33.8m
Jeffrey Stewart
Executive VP & Chief Commercial Officerno dataUS$15.35m0.0035%
€ 10.5m
Roopal Thakkar
Executive VP of Research and Development & Chief Scientific Officerless than a yearno data0.00092%
€ 2.7m
Elizabeth Shea
Senior Vice President of Investor Relationsno datano datano data
Perry Siatis
Executive VP2.2yrsno data0%
€ 0
Sanjay Narayan
Senior VP1.2yrsno datano data
Timothy Richmond
Executive VP & Chief Human Resources Officerno dataUS$3.30m0.00078%
€ 2.3m
Wulff-Erik von Borcke
Senior VP of AbbVie & President of Oncology1.2yrsno datano data
Nicholas Donoghoe
Executive VP and Chief Business & Strategy Officer1.9yrsno data0.0032%
€ 9.4m

1.2yrs

Average Tenure

55yo

Average Age

Experienced Management: 4AB's management team is not considered experienced ( 1.2 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Richard Gonzalez
Executive Chairman11.9yrsUS$25.66m0.022%
€ 65.5m
Robert Michael
CEO & Directorless than a yearUS$14.44m0.0056%
€ 16.6m
Roxanne Austin
Lead Independent Director11.9yrsUS$388.39k0.00065%
€ 1.9m
Thomas Freyman
Independent Director4.6yrsUS$389.98k0.0071%
€ 21.1m
Glenn Tilton
Independent Director11.9yrsUS$421.58k0.0014%
€ 4.2m
Edward Rapp
Independent Director11.9yrsUS$394.98k0.00090%
€ 2.7m
William H. Burnside
Independent Director11.9yrsUS$377.48k0%
€ 0
Frederick Waddell
Independent Director11.9yrsUS$369.98k0.00011%
€ 327.1k
Melody Meyer
Independent Director7.6yrsUS$369.98k0%
€ 0
Brett Hart
Independent Director8.9yrsUS$384.98k0%
€ 0
Rebecca Roberts
Independent Director6.6yrsUS$359.98kno data
Robert Alpern
Independent Director11.9yrsUS$461.18k0.000010%
€ 29.7k

11.9yrs

Average Tenure

70yo

Average Age

Experienced Board: 4AB's board of directors are seasoned and experienced ( 11.9 years average tenure).


Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 23:43
End of Day Share Price 2024/11/22 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

AbbVie Inc. is covered by 54 analysts. 27 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
David ToungArgus Research Company
Ishan MajumdarBaptista Research
Luisa HectorBerenberg